Literature DB >> 18774133

The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects.

Ki Chul Sung1, Marno C Ryan, Andrew M Wilson.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has been linked to cardiovascular disease (CVD) but it is largely unknown if such a relationship between NAFLD and CVD risk relates to severity of liver disease or if it is independent. We aimed to study the severity of NAFLD in a well characterized non-obese population and to compare this to prevalence of CVD risk factors and Framingham risk score.
METHODS: This study included 30,172 subjects. Based on the presence or absence of steatosis on ultrasound and serum alanine aminotransferase (ALT), subjects were divided into controls, an increased serum ALT group without steatosis and a group with presumed nonalcoholic fatty liver disease (NAFLD), which included a steatosis alone group and a group with presumed nonalcoholic steatohepatitis (NASH) with steatosis and an elevated ALT.
RESULTS: The odds ratio for 10-year risk by total Framingham risk scores > or =10% was 5.3 times higher in NASH groups. The prevalence of diabetes, hypertension, elevated CRP and metabolic syndrome were all increased up to 15-fold over controls, independent of age, BMI, smoking and exercise habits. Overall CVD risk was significantly greater in NASH than in either steatosis or raised ALT alone.
CONCLUSION: Young, non-obese subjects with NAFLD are at significantly increased CVD risk, especially those with NASH. As well as specific therapy for liver disease, a diagnosis of NAFLD should lead to targeted risk assessment and risk factor modification.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18774133     DOI: 10.1016/j.atherosclerosis.2008.07.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  40 in total

1.  Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Mitsuhito Koizumi; Shinya Furukawa; Teruhisa Ueda; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2012-02-14       Impact factor: 7.527

2.  A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients.

Authors:  Alex Ulitsky; Ashwin N Ananthakrishnan; Richard Komorowski; James Wallace; Sri Naveen Surapaneni; Jose Franco; Kia Saeian; Samer Gawrieh
Journal:  Obes Surg       Date:  2010-06       Impact factor: 4.129

Review 3.  Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction.

Authors:  Metin Basaranoglu; Gokcen Basaranoglu; Elisabetta Bugianesi
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

Review 4.  Non-alcoholic fatty liver disease - the heart of the matter.

Authors:  Haneen Azzam; Stephen Malnick
Journal:  World J Hepatol       Date:  2015-06-08

5.  Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012.

Authors:  Kenichi Nishioji; Yoshio Sumida; Mai Kamaguchi; Naomi Mochizuki; Masao Kobayashi; Takeshi Nishimura; Kanji Yamaguchi; Yoshito Itoh
Journal:  J Gastroenterol       Date:  2014-03-12       Impact factor: 7.527

6.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

7.  Hepatic steatosis in overweight/obese females: new screening method for those at risk.

Authors:  Giovanni Tarantino; Genoveffa Pizza; Annamaria Colao; Fabrizio Pasanisi; Paolo Conca; Patrizia Colicchio; Carmine Finelli; Franco Contaldo; Carolina Di Somma; Silvia Savastano
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

8.  Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease.

Authors:  Guldem Kilciler; Halil Genc; Serkan Tapan; Fatih Ors; Muammer Kara; Nuri Karadurmus; C Nuri Ercin; Yildirim Karslioglu; Selim Kilic; Sait Bagci; M Kemal Erbil; Teoman Dogru
Journal:  Ups J Med Sci       Date:  2010-08-23       Impact factor: 2.384

9.  Non-alcoholic Fatty Liver Disease: East Versus West.

Authors:  Swastik Agrawal; Ajay K Duseja
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

10.  Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.

Authors:  Alok K Gupta; George A Bray; Frank L Greenway; Corby K Martin; William D Johnson; Steven R Smith
Journal:  J Diabetes Complications       Date:  2009-07-04       Impact factor: 2.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.